ライフサイエンスコーパス: PRP

1 PRP activity remained unchanged in the untreated MPTP he

2 PRP activity was also stable (P >/= 0.29) and correlated

3 PRP activity was elevated in the untreated MPTP hemisphe

4 PRP activity was measured prospectively in all animals a

5 PRP and PPP showed a similar protein profile and exerted

6 PRP compared with IVR as primary treatment for PDR is le

7 PRP expressed antibacterial properties, which may be att

8 PRP formulation was proven to inhibit in vitro angiogene

9 PRP in this group of PDR patients did not have a statist

10 PRP increased cartilage surface cell density 1.5-fold (P

11 PRP interfered with P. gingivalis and A. actinomycetemco

12 PRP structures are dominated by four-sided right-handed

13 PRP- BMA presented higher numbers of PCNA-positive and B

14 PRP-BMA promoted NC formation with a functional periodon

15 ided into four groups: 1) C (control) and 2) PRP, defects were filled with blood clot or PRP, respect

16 ) of 22 IVB-treated eyes and in 1 (3%) of 32 PRP-treated eyes.

17 od clot or PRP, respectively; 3) LLLT and 4) PRP/LLLT, defects received laser irradiation, were fille

18 lative probability of worsening PDR was 42% (PRP) versus 34% (ranibizumab; hazard ratio [HR], 1.33; 9

19 in many states) at 2 years compared with 82 PRP participants (87%, adjusted risk ratio = 1.1, 95% CI

20 Additionally, PRP coacervate doubled the rate of wound contraction com

21 pproximately 27%; P = 0.002, 0.03) and after PRP (P = 0.002, 0.03).

22 bjects both at baseline (P = 0.01) and after PRP (P = 0.003).

23 01 and 0.017, respectively) as well as after PRP (P < 0.001 and 0.006, respectively).

24 was found in the PRF (55.41% +/- 11.39%) and PRP (56.85% +/- 14.01%) groups compared with the control

25 At 30 days, control and PRP-BMA groups presented similar amounts of NBA and ABT;

26 At 10 days, control and PRP-BMA groups presented similar amounts of NBA and ABT;

27 andomly divided into two groups, control and PRP-BMA, in which defects were filled with blood clot or

28 Both IVB and PRP are effective treatment options for type 1 ROP with

29 ent for zone I ROP eyes treated with IVB and PRP were -3.7 D and -10.1 D, respectively, and for zone

30 PRF (3.77 +/- 1.19 and 3.17 +/- 1.29 mm) and PRP (3.77 +/- 1.07 and 2.93 +/- 1.08 mm) groups than the

31 At this time, MSCs and PRP require more investigation.

32 Distinguishing the effects of PDR and PRP may guide the development of restorative vision ther

33 es were compared among patients with PDR and PRP, untreated patients with PDR, and controls.

34 racterize and compare the effects of PPP and PRP on bone healing in vivo.

35 Assays on reconstituted PRP and PRP from fibrinogen-deficient patients revealed a fibrin

36 Groups LLLT, PRP, and PRP/LLLT showed significant NC formation at 30 days, wit

37 g DME, 80 and 87 were in the ranibizumab and PRP groups, respectively.

38 rofiles with hypoxia or oxidative stress and PRP-overexpressing plants have elevated levels of reacti

39 ne and post-Hib-MenC booster responses (anti-PRP IgG and memory B cells) were found in younger childr

40 with 3 doses of Hib conjugate vaccine, anti-PRP IgG geometric mean concentrations were 3.11 microg/m

41 and 0.71 microg/mL and proportions with anti-PRP IgG >/=1.0 microg/mL were 79% and 43% in children wh

42 The findings reveal that locally applied PRP enhanced the maturity of the healing tendon tissues

43 mparable results with the conventional argon PRP in the treatment of patients with diabetic retinopat

44 ch plasma derived from bone marrow aspirate (PRP-BMA) on the healing of periodontal fenestration defe

45 As datamining associates PRP expression profiles with hypoxia or oxidative stress

46 PRF with open-flap debridement or autologous PRP with open-flap debridement or open-flap debridement

47 viously described method, immediately before PRP treatment and 7 to 8 weeks after the last PRP sessio

48 rage lifetime, the cost differential between PRP and IVR increases, and IVR therapy may exceed the ty

49 ve patients with PDR that required bilateral PRP.

50 Compared with blood, PRP reconstituted with PPP to a physiologic platelet con

51 rols (1.80+/-0.14) also was observed in both PRP-treated patients (1.42+/-0.17; P < 0.0001) and untre

52 Bacterial growth inhibition by PRP occurred in the first 24 hours after application in

53 We identified L-18F-FMAU as a candidate PRP and determined its biodistribution in mice and human

54 Self-setting alginate hydrogel carrying PRP was tested on a femur defect model ex vivo.

55 the PRP by progressively syphoning clarified PRP away from the concentrated leukocyte flowstream.

56 The combination PRP/LLLT did not show additional positive effects compar

57 Consequently, PRP could have relevant oncological clinical application

58 d platelets or immunoglobulin (Ig)G-depleted PRP.

59 IgG or monoclonal IgG1 added to IgG-depleted PRP increased the lag time in response to 5B9.

60 both enhance PRP photodegradation and divert PRP dissipation processes away from the production of 34

61 ined use of autologous fibrin membrane and E-PRP clot is a safe and effective surgical alternative fo

62 membrane and the eye platelet-rich plasma (E-PRP) clot could be considered as a new surgical alternat

63 n membrane to the conjunctiva and then the E-PRP clot was placed over the corneal perforation, undern

64 Both the fibrin membrane and the E-PRP clot were prepared with the patient's own blood just

65 Four sites in the EMD + PRP + NBM group lost 1 mm of the CAL gained at 1 year.

66 rrigation with such water would both enhance PRP photodegradation and divert PRP dissipation processe

67 At enrollment, PRP symptoms had persisted in 36 patients (72%) for an a

68 In the natural environment, we expect PRP photodegradation to be important only in the presenc

69 Filtrate PRP collected from an optimally-designed CIF device typi

70 line, but did not decrease further following PRP, with important implications related to diabetes con

71 For PRP and FP, sensitivities were 90.4% and 74.0%, respecti

72 s (D) and 22.4 months, respectively, and for PRP-treated eyes, these were -5.3 D and 37.1 months, res

73 although longer follow-up was available for PRP.

74 tituted for the conventional argon laser for PRP in many clinics.

75 treatments broadens therapeutic options for PRP in proliferative diabetic retinopathy.

76 Cost utility for PRP would be 85% lower than IVR in the facility setting

77 all other treatments, including that of free PRP proteins.

78 At 10 days, group PRP presented ERD significantly lower than group C.

79 At 30 days, group PRP presented NB and DNB significantly greater than grou

80 es of 45 patients with PDR, PRP (PRP group), PRP with IVT (IVT group), or PRP with IVB (IVB group) wa

81 PRP were randomly assigned to 1 of 4 groups: PRP conventional pattern 30 ms, 100 ms, navigated patter

82 es with 2 years of follow-up, 43 (62.3%) had PRP, 16 (23.2%) were treated with injections alone, and

83 Of the 111 eligible eyes, 55 (49.5%) had PRP, 35 (31.6%) were managed with injections alone, and

84 nion exchange chromatography with a Hamilton PRP-X100 column as the stationary phase.

85 However, PRP can damage the retina, resulting in peripheral visio

86 However, PRP samples had fewer blood vessels than did control sam

87 In conclusion, administration of human PRP attenuates brain injury after focal ischemia.

88 eived local intra-arterial infusion of human PRP lysate (p's<0.05).

89 otential benefits of administration of human PRP lysate after ischemic stroke in rats.

90 oke rats received systemic infusion of human PRP lysate to further assess the therapeutic effects of

91 saline, and systemic administration of human PRP lysate, compared to no treatment significantly reduc

92 local infusion to the ischemic area of human PRP lysate, human albumin solution (HSA), saline or no t

93 , masked, clinical trial was to determine if PRP combined with a rapidly resorbing cancellous allogra

94 In PRP-treated eyes, retinal detachment developed in only 1

95 cipants (104 in aflibercept group and 106 in PRP group) within per protocol.

96 rticipants (112 in aflibercept group, 109 in PRP group) contributed to the modified intention-to-trea

97 ase report, a role of the IL-23-TH17-axis in PRP was identified, suggesting a shared pathogenic infla

98 of FDP mean deviation (MD) was exhibited in PRP-treated patients with PDR (MD +/- standard deviation

99 nt of collagen I was significantly higher in PRP-treated tendons than in control tendons (p=0.0079),

100 glycans content were significantly higher in PRP-treated tendons than in controls (p=0.01 and p<0.001

101 III to collagen I was significantly lower in PRP samples (p=0.007).

102 ified Bonar score was significantly lower in PRP samples, which indicates improved early tendon heali

103 s between the groups tested, TGA measured in PRP with CTI best differentiated between bleeders and no

104 rns specific for maturation were mimicked in PRP treated cartilage, with chondromodulin, collagen typ

105 sely, PLS male offspring showed lower NPY in PRP, a 10-fold decrease of Y2R mRNA in VAT, lower adipos

106 tokine profile, targeted treatment option in PRP.

107 Contact phase activation by polyphosphate in PRP resulted in 75% cleavage of chem163S.

108 (*)OH and CO3(*-) would play a major role in PRP phototransformation.

109 okines IL-17A, IL-17F, and IL-22 was seen in PRP.

110 Contrast sensitivity remained stable in PRP and IVB groups and slightly decreased in IVT group.

111 e number of sittings to complete the initial PRP.

112 investigating the effects of multispot laser PRP on retinal sensitivity demonstrates a high likelihoo

113 RP treatment and 7 to 8 weeks after the last PRP session.

114 In lesional PRP skin samples from a single patient, upregulated expr

115 LLLT, PRP, or their combination all promoted NC formation with

116 Groups LLLT, PRP, and PRP/LLLT showed significant NC formation at 30

117 In a porcine model, PRP coacervate significantly accelerated the healing res

118 nogen A was determined at a ratio 1:6 (named PRP) using 24 human cancer cell lines.

119 12) of the defects treated with EMD + NBM + PRP and in 100% (all 12) of the defects treated with EMD

120 The sites treated with EMD + NBM + PRP demonstrated a mean CAL change from 10.5 +/- 1.6 to

121 ep intrabony defects with either EMD + NBM + PRP or EMD + NBM.

122 was randomly treated with either EMD + NBM + PRP or EMD + NBM.

123 ed proliferation of MSCs, and 2.5% to 10% of PRP gradually increased alkaline phosphatase (ALP) activ

124 Atomic force microscopy analysis of PRP and growth factor treated cartilage gave a 5-fold in

125 The application of PRP on periodontal surgical sites is advisable because o

126 thors evaluated the growth factor content of PRP and PPP using a proteome profiler array and enzyme-l

127 hemical (probably biological) degradation of PRP.

128 undred patients with a putative diagnosis of PRP and who elected to participate completed a comprehen

129 Patients with a diagnosis of PRP were solicited through patient support organization

130 ined osteogenic and mineralization effect of PRP and BMP2 on MSCs was studied.

131 The effect of PRP and PPP on HPLSC bone differentiation was analyzed b

132 The effect of PRP at day 15 on the closure of the embryonic mouse calv

133 The antiangiogenic effect of PRP was analysed by matrigel-based tube formation and by

134 no published study exists of the effects of PRP in human tissues in vivo.

135 as developed to minimize the side effects of PRP.

136 Transgenic over-expression of PRP, the founding member, led to plants with enhanced re

137 s were graded for the presence and extent of PRP and FP.

138 subject reporting and photograph grading of PRP and FP were compared in EDIC subjects.

139 ately reported whether they had a history of PRP in one or both eyes, and 1259 (97.5%) of 1291 with v

140 isual acuity 20/320 or better, no history of PRP.

141 ity (VA) 20/320 or better, and no history of PRP.

142 Increase of PRP concentration promoted proliferation of MSCs, and 2.

143 rative diabetic retinopathy (PDR) in need of PRP were randomly assigned to 1 of 4 groups: PRP convent

144 ese results suggest that this preparation of PRP accelerates healing of cutaneous wounds only as a co

145 rentiation in vitro and sustained release of PRP alone on a fracture defect model ex vivo as well as

146 Sustained release of PRP along with BMP2-modified MSCs can significantly prom

147 Sustained release of PRP and BMP2 demonstrated significantly higher ALP and m

148 the combined effect of sustained release of PRP from alginate beads on BMP2-modified MSC osteogenic

149 up to a period of 5 years; and 2) the use of PRP does not appear to improve the results obtained with

150 ermine the longer term effects of the use of PRP in musculoskeletal diseases.

151 LTC4 was fully active on PRP from mice lacking either CysLT1R or GPR99, but compl

152 ivation, was quantified by flow cytometry on PRP.

153 Despite accumulating evidence on PRP's safety and efficacy for treating musculoskeletal i

154 CysLT1R or GPR99, but completely inactive on PRP from CysLT2R-null (Cysltr2(-/-)) mice.

155 surement is especially important to optimize PRP for applications using short pulse duration.

156 irradiation, were filled with blood clot or PRP, respectively, and then irradiated again.

157 PRP, defects were filled with blood clot or PRP, respectively; 3) LLLT and 4) PRP/LLLT, defects rece

158 which defects were filled with blood clot or PRP-bma, respectively.

159 und responses to IBU and CFA, but not CTZ or PRP.

160 RP (PRP group), PRP with IVT (IVT group), or PRP with IVB (IVB group) was performed.

161 data from infants treated with either IVB or PRP for type 1 ROP between 2008 and 2012 were recorded f

162 ibercept injections were given as needed) or PRP standard care (single spot or mutlispot laser at bas

163 , and bone fill at sites treated with PRF or PRP with conventional open-flap debridement.

164 ased on a structured retreatment protocol or PRP at baseline for PDR.

165 ng-related outcomes favored ranibizumab over PRP, no differences between treatment regimens for PDR w

166 ch, a Pro-rich domain, and a C-terminal PAC (PRP-AGP containing Cys) domain.

167 ed a parkinsonism-related metabolic pattern (PRP) in nonhuman primate models of PD.

168 In 60 eyes of 45 patients with PDR, PRP (PRP group), PRP with IVT (IVT group), or PRP with I

169 ess visual field loss, continuing to perform PRP may be justified.

170 such as the Psychological Refractory Period (PRP) has only been quantified in discrete movement condi

171 Anti-polyribosylribitol phosphate (PRP) immunoglobulin G (IgG) concentration and the freque

172 anaged by panretinal laser photocoagulation (PRP) for the past 40 years.

173 report of prior panretinal photocoagulation (PRP) and focal photocoagulation (FP) compared with fundu

174 Panretinal photocoagulation (PRP) for proliferative diabetic retinopathy (PDR) may le

175 Panretinal photocoagulation (PRP) is the standard treatment for reducing severe visua

176 es treated with panretinal photocoagulation (PRP) or ranibizumab.

177 DR treated with panretinal photocoagulation (PRP) using either argon green laser (41 eyes treated bef

178 alternative to panretinal photocoagulation (PRP) when managing proliferative diabetic retinopathy (P

179 injections, and panretinal photocoagulation (PRP), as well as visual acuity at baseline and at 1 year

180 hotographs, (2) panretinal photocoagulation (PRP), or (3) pars plana vitrectomy (PPV) for PDR; and st

181 Pan retinal photocoagulation (PRP) has provided an effective treatment to decrease the

182 Pityriasis rubra pilaris (PRP) is a rare papulosquamous disorder with limited epid

183 Treatment of pityriasis rubra pilaris (PRP) is solely based on its resemblance to psoriasis rat

184 vulgaris (PV) and pityriasis rubra pilaris (PRP).

185 ype mouse platelets in platelet-rich plasma (PRP) and caused their secretion of thromboxane A2 and CX

186 pecific effect of both platelet-rich plasma (PRP) and platelet-poor plasma (PPP) on osteoblastic diff

187 The comparison used platelet-rich plasma (PRP) and platelet-poor plasma (PPP), either with or with

188 icrobial activities of platelet-rich plasma (PRP) and related plasma preparations against periodontal

189 Platelet-rich plasma (PRP) consists of platelet-derived growth factor and tran

190 Platelet-rich plasma (PRP) contains a number of biologically active growth fac

191 ate (MGCSH) mixed with platelet-rich plasma (PRP) for extraction socket preservation graft before imp

192 nd without addition of platelet-rich plasma (PRP) has been shown to result in substantial clinical im

193 rticular injections of platelet-rich plasma (PRP) has not produced clear evidence that this therapy i

194 val of leukocytes from platelet-rich plasma (PRP) in a continuous flow regime.

195 -rich fibrin (PRF) and platelet-rich plasma (PRP) in the treatment of intrabony defects in patients w

196 Platelet-rich plasma (PRP) is a milieu of bioactive factors, including platele

197 Platelet-rich plasma (PRP) is used to stimulate the repair of acute and chroni

198 Platelet-rich plasma (PRP) is widely used for many clinical indications includ

199 thrombin assays using platelet-rich plasma (PRP) showed that tissue factor-triggered thrombin genera

200 rophotometric assay on platelet-rich plasma (PRP) treated with the thromboxane A2 mimetic U46619, col

201 s) were performed with platelet-rich plasma (PRP), a shorter lag time was measured in 131RR donors co

202 Platelet-rich plasma (PRP), an autologous derivative of whole blood that conta

203 lyzes the influence of platelet-rich plasma (PRP), low-level laser therapy (LLLT), or their combinati

204 ed blood cells (RBCs), platelet-rich plasma (PRP), platelet-poor plasma (PPP), and buffy coat.

205 ulation assay in human platelet rich plasma (PRP).

206 d markedly enhanced in platelet-rich plasma (PRP).

207 -AP and incubated with platelet-rich plasma (PRP).

208 n addition to elevated platelet-rich-plasma (PRP) NPY, compared to control females fed a high-fat die

209 characterization of photorefractive polymer (PRP) in a previously inaccessible regime located between

210 e and activated capsular polyribosylribitol (PRP) polysaccharides extracted from Haemophilus influenz

211 ggest that the TK2-N93D/L109F/L-18F-FMAU PRG-PRP system warrants further evaluation in preclinical an

212 Here we describe a new PRG-PRP system that employs, as the PRG, a mutated form of h

213 pecifically accumulate a PET reporter probe (PRP) and can be detected by PET imaging.

214 n irradiated in paddy-field water, propanil (PRP) undergoes photodegradation by direct photolysis, by

215 (CTZ), clofibric acid (CFA) and propranolol (PRP), found responses to IBU and CFA, but not CTZ or PRP

216 atekinase in the primer recognition protein (PRP) complex that interacts with DNA polymerase alpha in

217 s thaliana is a pentapeptide-repeat protein (PRP) composed of 25 repeats capped by N- and C-terminal

218 In 60 eyes of 45 patients with PDR, PRP (PRP group), PRP with IVT (IVT group), or PRP with IVB (I

219 eived a cancellous allograft mixed with PRP (PRP group).

220 25 and UAB-LLQ composite scores, ranibizumab-PRP treatment group differences (95% CI) were +4.0 (-0.2

221 idual eyes were randomly assigned to receive PRP treatment, completed in 1 to 3 visits (n = 203 eyes)

222 ived IVB, and 32 eyes (17 patients) received PRP.

223 respectively, and for the infants receiving PRP, these were 24.8 weeks, 701.4 g, 36.1 weeks, and 34.

224 Assays on reconstituted PRP and PRP from fibrinogen-deficient patients revealed

225 pathway as a treatment option for refractory PRP.

226 ipitous therapeutic approaches in refractory PRP.

227 om this patient and 2 others with refractory PRP.

228 values were calculated for subject-reported PRP and FP.

229 might be used to counsel patients requiring PRP and informs the debate regarding the role of anti-va

230 When using traditional laser settings, PRP performed with the PASCAL is less effective than tha

231 ings were highly reproducible across several PRP topographies generated in multiple cohorts of parkin

232 rotein that regulates translation of several PRP RNAs in neurons.

233 These data show PRP induces key aspects of post-natal maturation in imma

234 elevated levels of reactive oxygen species, PRP may connect MAPK and oxidative stress signaling.

235 ive in the context of psoriasis and sporadic PRP.

236 cral pustular psoriasis (n=100), or sporadic PRP (n=29).

237 pattern scan versus conventional single-spot PRP also were at higher risk for worsening PDR (60% vs.

238 Our results suggest PRP should be investigated further as a potential point-

239 IVB was associated with less myopia than PRP, although longer follow-up was available for PRP.

240 ead to a greater reduction of active NV than PRP alone in PDR, although no differences were seen betw

241 , it may seem a better treatment option than PRP.

242 requires a more frequent visit schedule than PRP, these findings provide additional evidence supporti

243 ity that was noninferior to (not worse than) PRP treatment at 2 years.

244 ions of the embryonic calvaria revealed that PRP leads to suture fusion.

245 linical and histologic findings suggest that PRP enhanced bone regeneration and resulted in increased

246 resented similar amounts of NBA and ABT; the PRP-BMA group showed NC formation with collagen fibers i

247 macokinetic studies were implemented and the PRP's anti-tumour efficacy was explored against orthotop

248 L-arabinofuranosyluracil (L-18F-FMAU) as the PRP.

249 7% for the CAN group and 28% +/- 17% for the PRP group (P >0.05).

250 CAN group compared with 51% +/- 15% for the PRP group and was statistically significant between grou

251 Changes in CMT in the PRP and IVT groups were not significant, but significant

252 +2.8 in the ranibizumab group vs +0.2 in the PRP group (difference, +2.2; 95% CI, -0.5 to +5.0; P < .

253 f the tissue was significantly better in the PRP group than in the control tissue (p<0.001).

254 ence, 19%; 95% CI, 10%-28%; P < .001) in the PRP group vs the ranibizumab group, respectively.

255 ctive NV and BCVA were 3.45 and 67.35 in the PRP group, 4.35 and 76.65 in the IVT group, and 4.79 and

256 In the PRP group, eyes receiving pattern scan versus convention

257 (35% in the ranibizumab group vs 30% in the PRP group; difference, 3%; 95% CI, -7% to 12%; P = .58).

258 = 0.011), and 0.9 letters (P = 0.628) in the PRP, IVT, and IVB groups, respectively.

259 igned to the ranibizumab group and 25 to the PRP group (plus ranibizumab for DME).

260 d a mean gain of 2.0 +/- 1.2 mm, whereas the PRP group gained 2.9 +/- 1.0, and the difference was sta

261 ytes are separated from platelets within the PRP by progressively syphoning clarified PRP away from t

262 apid enhancement of bone healing compared to PRP-free collagen resorbable graft.

263 Only the addition of RBCs to PRP was capable of normalizing alphaTAT generation.

264 Aflibercept was non-inferior and superior to PRP in both the modified intention-to-treat population (

265 esponse of ruptured human Achilles tendon to PRP.

266 of ranibizumab as an alternative therapy to PRP for PDR, at least through 2 years.

267 ked by EDIC staff whether they had undergone PRP, FP, or both since the last completed annual clinic

268 Patients who underwent PRP had diffusely thickened nerve fiber layers (P = 0.02

269 Patients who underwent PRP had more profound changes in outer retinal structure

270 diagnosed as having classic, unquestionable PRP.

271 s, limited studies have been performed using PRP in brain disorders.

272 ness ratios of 0.5-mg ranibizumab therapy vs PRP for PDR.

273 When PRP was the primary treatment, the 2-year cost in the fa

274 parative study in order to determine whether PRP can also induce this specific form of remodeling tha

275 A mechanism in which PRP-topoisomerase poison resistance factors bind to and

276 Factors associated with PRP included recipients' educational attainment, insuran

277 e of both triamcinolone and bevacizumab with PRP lead to a greater reduction of active NV than PRP al

278 tiveness ratios of ranibizumab compared with PRP evaluated within 2 prespecified subgroups for the st

279 ratios of ranibizumab therapy compared with PRP were $55568/quality-adjusted life-year and $662978/q

280 Over 2 years, compared with PRP, 0.5-mg ranibizumab as given in this trial is within

281 resulted in less PDR worsening compared with PRP, especially in eyes not required to receive ranibizu

282 , the rate of PDR-worsening was greater with PRP than ranibizumab (45% vs. 31%; HR, 1.62; 99% CI, 1.0

283 parations can inhibit bacterial growth, with PRP showing the superior activity.

284 Radiographs of alginate hydrogel with PRP-treated bone demonstrated nearly complete healing of

285 4 received a cancellous allograft mixed with PRP (PRP group).

286 .4% in sockets grafted with MGCSH mixed with PRP compared to 38.3% +/- 9.3% collagen resorbable plug.

287 patients randomly received MGCSH mixed with PRP in the extraction sockets (test group), and eight se

288 MGCSH mixed with PRP showed greater vital bone volume at 3 months with ra

289 In this case report, a patient with PRP received outpatient treatment at a university hospit

290 The patient with PRP who received ustekinumab showed regression of skin l

291 etime therapy yielded the cost per QALY with PRP treatment of $14 219 to $24 005 and with IVR of $138

292 were assessed every 8 weeks and treated with PRP as needed) for 52 weeks.

293 Wounds treated with PRP coacervate exhibited increased collagen alignment an

294 ompared with controls, patients treated with PRP demonstrated increased photostress recovery time (15

295 e at 1 year compared with those treated with PRP standard care.

296 umber of zone I and II ROP eyes treated with PRP were 5 and 27, respectively.

297 performed on human cancer cells treated with PRP.

298 nse of ruptured Achilles tendon treated with PRP.

299 Achilles tendon 6 weeks after treatment with PRP or placebo controls (10 patients each).

300 ve result compared with an allograft without PRP.